Karen Carey

CoTherix Acquires Schering's U.S. Rights For Ventavis, Raises $55M

Oct. 15, 2003

The company formerly known as Exhale Therapeutics Inc. has acquired a new name, a new financing and new U.S. rights to a pulmonary hypertension product. (BioWorld Today)

Xcyte Seeking $75M In Second Attempt At Initial Public Offering

Oct. 14, 2003

By Karen Carey

XOMA, Millennium Drop Heart Drug; CAB-2 Product Remains

Oct. 13, 2003

By Karen Carey

ID Biomedical Raising $100M To Advance FluINsure, StreptAvax

Oct. 10, 2003

By Karen Carey

CTI Raises $56M In Series B; Asthma Product To Benefit

Oct. 9, 2003

By Karen Carey

IntraBiotics Raises $19.2M For Pivotal Iseganan Trials

Oct. 8, 2003

By Karen Carey

Cubist Signs Chiron As Ex-U.S. Partner For Cubicin Marketing

Oct. 6, 2003

By Karen Carey

Nuvelo Raises $24.5M For Alfimeprase, In-Licensing

Oct. 3, 2003

By Karen Carey

PDL Regains Roche's Zenapax Rights In Non-Transplantation

Oct. 1, 2003

By Karen Carey

With the intention of developing the approved drug Zenapax in other indications, Protein Design Labs Inc. restructured its commercial deal with Hoffmann-La Roche Inc. regaining exclusive worldwide rights in all indications other than organ transplantation. (BioWorld Today)